Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
James Burton, DM, FRCP
Javed Butler, MD, MPH, MBA
Future Directions in Managing Hyperkalemia in CKD and HF
Potassium Binders in Practice: Clinical Trial Evidence
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Potassium Binders: Safety Comes First!
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
The Clinical Weight of TTR: What the Latest Data Reveal
Ahmad Masri, MD, MS
Rola Khedraki, MD
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Optimizing Barostim Outcomes: Practical Approaches to Patient Selection and Monitoring
Cynthia J. Bither, ACNP-BC, MSN
Andrea Wallace, MSN, FNP-C, HF-Cert
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA